NCT06374823Not yet recruitingPhase 4
Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke
The Impact of Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke Patients: A Prospective, Multicenter, Open-label, Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 19 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Normal saline (0.9% sodium chloride), a classical crystalloid solution, is widely used to maintain fluid balance, volume resuscitation and dilute drugs during clinical practice. However, the chloride concentration of normal saline (154mmol/L) is much higher than human plasma, and a large amount of infusion may lead to iatrogenic hyperchloremia in ICU patients. In contrast, the concentrations of Multiple electrolytes II is more similar to those of plasma and is considered to be a better fluid choice than normal saline.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 342 (estimated)
- First submitted
- 16 Apr 2024
- Start date
- May 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Capital Medical University
- Diseases
- Stroke
- NCT number
- NCT06374823
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 342
- From May 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving routine RRT
Other illness
- Hemorrhage onset more than 72hours
- Presence of hypothalamic disease or cerebral salt wasting syndrome
- Patients with known allergic or adverse reactions to the liquid used
- Patients with organ failure (such as heart failure, renal failure, liver failure) or end-stage disease
- Patients with autoimmune diseases, inflammatory diseases, metabolic diseases and blood diseases
- Patients with serious heart disease or arrhythmia
- Other conditions deemed by the investigator to be ineligible for participation in the study
Other
- Preexisting hyperchloremia(blood chloride \> 110mmol/L)
- Patients who can eat by themselves
- Patients who are expected to have difficulty complying with the study plan or collecting data completely
- Pregnant or lactating women
- No informed consent was signed
- Patients participating in other clinical trials
Who the study is looking for
- Patients with a diagnosis of hemorrhagic stroke (cerebral hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage confirmed by CT or MRI, except for subdural or extradural hemorrhage caused by tramma)
- Patients requiring fluid therapy
- Patients over 18 years old
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Shijitan Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.